【中信里昂：上调复星医药(02196.HK)目标价至29.6港元 重申“跑赢大市”评级】智通财经APP获悉，中信里昂发布研报称，上调复星医药(02196.HK)H股目标至29.6港元，A股目标价上调至40.2元人民币，重申A股与H股“跑赢大市”评级。报告指，对整个行业的估值上调以及子公司复宏汉霖(02696.HK)的强劲股价表现，将复星医药的目标市盈率从10.3倍上调至18倍。该行认为复星医药有望在创新药业务的驱动下重回加速增长轨道，较行业平均水平仍存在估值修复空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.